# MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC

> **NCT05286957** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital of Zhengzhou University** · enrollment: 60 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** adjuvant tislelizumab and chemotherapy for MRD+ patients
- **DRUG:** adjuvant tislelizumab and chemotherapy for MRD+ patients
- **DRUG:** adjuvant chemotherapy for MRD- patients

## Key facts

- **NCT ID:** NCT05286957
- **Lead sponsor:** The First Affiliated Hospital of Zhengzhou University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-20
- **Primary completion:** 2026-06-01
- **Final completion:** 2027-06-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05286957

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05286957, "MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05286957. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*